Alan P. Johnson
Research Subjects
Alan P. Johnson has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Marina Warner
Antibiotic Resistance Monitoring and Reference Laboratory, Specialist Reference Microbiology Division, HPA Centre for Infections, Colindale, London NW9 5HT, UK
4 shared publicationsDavid M. Livermore
3 shared publicationsGeorgia Duckworth
Department of Healthcare-Associated Infection and Antimicrobial Resistance , HPA Centre for Infections , Colindale, London NW9 5EQ , UK
3 shared publicationsRobert C. George
3 shared publicationsAndrew Pearson
Department of Healthcare-Associated Infection and Antimicrobial Resistance , HPA Centre for Infections , Colindale, London NW9 5EQ , UK
2 shared publicationsElizabeth Miller
2 shared publications
Latest Publications
- Open Access
- 3 August 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (12) , 2788-2792
Fidaxomicin: a new option for the treatment of Clostridium difficile infection
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and metronidazole, are both associated with high rates of recurrence of infection. Hence there is a need for new treatment options. The novel oral macrocyclic antibiotic fidaxomicin (previously known as PAR-101, OPT-80 and difimicin) was recently approved in the USA and in Europe for the treatment of CDI. Clinical trials have shown non-inferiority with regard to clinical cure when compared with oral vancomycin, and reduced rates of recurrence of infection, with a concomitant increase in the overall rate of sustained response, although improved sustained response was not seen in the sub-group of patients infected with the C. difficile NAP1/B1/027 strain. The introduction of fidaxomicin extends the options for the treatment of CDI and may help to reduce the burden of this disease if fewer patients have recurrence of infection.
- 3 August 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (12) , 2788-2792
Open AccessFidaxomicin: a new option for the treatment of Clostridium difficile infection
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and metronidazole, are both associated with high rates of recurrence of infection. Hence there is a need for new treatment options. The novel oral macrocyclic antibiotic fidaxomicin (previously known as PAR-101, OPT-80 and difimicin) was recently approved in the USA and in Europe for the treatment of CDI. Clinical trials have shown non-inferiority with regard to clinical cure when compared with oral vancomycin, and reduced rates of recurrence of infection, with a concomitant increase in the overall rate of sustained response, although improved sustained response was not seen in the sub-group of patients infected with the C. difficile NAP1/B1/027 strain. The introduction of fidaxomicin extends the options for the treatment of CDI and may help to reduce the burden of this disease if fewer patients have recurrence of infection.
- Open Access
- 4 January 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (4) , 802-809
Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years
Since 2001 it has been mandatory for acute hospital Trusts (groups of hospitals under the same management) in England to report all cases of bacteraemia due to Staphylococcus aureus together with information on their susceptibility or resistance to methicillin. This allowed the incidence of methicillin-resistant S. aureus (MRSA) bacteraemia (expressed as the number of cases per 1000 occupied bed days) to be determined for each Trust. In late 2005, the scheme was enhanced to collect demographic, clinical and epidemiological information on each case using a web-based data collection system. Analysis of this mandatory dataset has provided important information on the trends in MRSA bacteraemia in England and has documented a year-on-year decrease in incidence since 2006, following a government initiative in which Trusts were tasked with halving their MRSA bacteraemia rates over a 3year period. In addition, the enhanced mandatory surveillance scheme has captured a wealth of data that have helped to further define the epidemiology of MRSA bacteraemia. It is to be hoped that based on the English experience of mandatory surveillance, other countries will consider the implementation of similar schemes, not only for MRSA but for other pathogens of public health importance.
- 4 January 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (4) , 802-809
Open AccessMandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years
Since 2001 it has been mandatory for acute hospital Trusts (groups of hospitals under the same management) in England to report all cases of bacteraemia due to Staphylococcus aureus together with information on their susceptibility or resistance to methicillin. This allowed the incidence of methicillin-resistant S. aureus (MRSA) bacteraemia (expressed as the number of cases per 1000 occupied bed days) to be determined for each Trust. In late 2005, the scheme was enhanced to collect demographic, clinical and epidemiological information on each case using a web-based data collection system. Analysis of this mandatory dataset has provided important information on the trends in MRSA bacteraemia in England and has documented a year-on-year decrease in incidence since 2006, following a government initiative in which Trusts were tasked with halving their MRSA bacteraemia rates over a 3year period. In addition, the enhanced mandatory surveillance scheme has captured a wealth of data that have helped to further define the epidemiology of MRSA bacteraemia. It is to be hoped that based on the English experience of mandatory surveillance, other countries will consider the implementation of similar schemes, not only for MRSA but for other pathogens of public health importance.
- Open Access
- 14 November 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (2) , 517
Kucers' The Use of Antibiotics, Sixth Edition
The sixth edition of this well-known text, which now comprises two volumes, contains a wealth of information on anti-infective drugs. Despite the use of the word ‘Antibiotics’ in the title, there are sections on antibacterial drugs (i.e. antibiotics), antifungals, antiparasitic drugs and antivirals. Each section is divided into a number of parts, each focusing on a class of anti-infective; these in turn comprise a series of chapters on individual drugs. Thus, for example, the antibiotics section has a part on aminoglycosides, which comprises chapters on kanamycin, gentamicin, tobramycin, amikacin, sisomicin and netilmicin, isepamicin and neomycin. The individual chapters broadly follow a uniform format with information on chemical structure, spectrum of antimicrobial activity (including emergence of resistance), mode of action, administration and dosage, pharmacokinetics and pharmacodynamics, toxicity and clinical use. Thus, it is a useful source of information for both the laboratory worker (in either a research or routine laboratory) and the practising clinician.
- 14 November 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (2) , 517
Open AccessKucers' The Use of Antibiotics, Sixth Edition
The sixth edition of this well-known text, which now comprises two volumes, contains a wealth of information on anti-infective drugs. Despite the use of the word ‘Antibiotics’ in the title, there are sections on antibacterial drugs (i.e. antibiotics), antifungals, antiparasitic drugs and antivirals. Each section is divided into a number of parts, each focusing on a class of anti-infective; these in turn comprise a series of chapters on individual drugs. Thus, for example, the antibiotics section has a part on aminoglycosides, which comprises chapters on kanamycin, gentamicin, tobramycin, amikacin, sisomicin and netilmicin, isepamicin and neomycin. The individual chapters broadly follow a uniform format with information on chemical structure, spectrum of antimicrobial activity (including emergence of resistance), mode of action, administration and dosage, pharmacokinetics and pharmacodynamics, toxicity and clinical use. Thus, it is a useful source of information for both the laboratory worker (in either a research or routine laboratory) and the practising clinician.
- Open Access
- 26 April 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (Supplement) , iv43-iv48
Methicillin-resistant Staphylococcus aureus: the European landscape
Pan-European surveillance of bacteraemia caused by methicillin-resistant Staphylococcus aureus (MRSA) shows it to be a problem affecting all European countries, although there is marked geographical variation in prevalence. Although the proportion of S. aureus bacteraemia due to MRSA is declining in many countries, data from the European Antimicrobial Resistance Surveillance System (EARSS) for 2008 showed that in more than one-third of countries the proportion remained >25%. In contrast to bacteraemia, community-associated MRSA infection in Europe remains relatively uncommon. However, there appears to be an increasing problem involving transmission of MRSA (particularly sequence type 398) from colonized livestock, particularly pigs, to farm workers, abattoir workers and veterinarians who are in contact with such animals. Molecular analysis of isolates of MRSA has shown that there has been spread of only a limited number of MRSA clones in Europe and that many of these clones show geographical clustering due to dissemination through regional healthcare networks. Despite our increasing understanding of the epidemiology of MRSA in Europe, MRSA infections continue to pose a significant public health challenge.
- 26 April 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (Supplement) , iv43-iv48
Open AccessMethicillin-resistant Staphylococcus aureus: the European landscape
Pan-European surveillance of bacteraemia caused by methicillin-resistant Staphylococcus aureus (MRSA) shows it to be a problem affecting all European countries, although there is marked geographical variation in prevalence. Although the proportion of S. aureus bacteraemia due to MRSA is declining in many countries, data from the European Antimicrobial Resistance Surveillance System (EARSS) for 2008 showed that in more than one-third of countries the proportion remained >25%. In contrast to bacteraemia, community-associated MRSA infection in Europe remains relatively uncommon. However, there appears to be an increasing problem involving transmission of MRSA (particularly sequence type 398) from colonized livestock, particularly pigs, to farm workers, abattoir workers and veterinarians who are in contact with such animals. Molecular analysis of isolates of MRSA has shown that there has been spread of only a limited number of MRSA clones in Europe and that many of these clones show geographical clustering due to dissemination through regional healthcare networks. Despite our increasing understanding of the epidemiology of MRSA in Europe, MRSA infections continue to pose a significant public health challenge.
- 11 August 2010
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 20 (10) , 1389-1399
New antibiotics for selective treatment of gastrointestinal infection caused byClostridium difficile
(2010). New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opinion on Therapeutic Patents: Vol. 20, No. 10, pp. 1389-1399. doi: 10.1517/13543776.2010.511177
- 11 August 2010
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 20 (10) , 1389-1399
New antibiotics for selective treatment of gastrointestinal infection caused byClostridium difficile
(2010). New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opinion on Therapeutic Patents: Vol. 20, No. 10, pp. 1389-1399. doi: 10.1517/13543776.2010.511177
- 1 June 2010
- Published by BMJ in Archives of Disease in Childhood
- Vol. 95 (10) , 781-785
Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland
Objective To determine the incidence and demographic features of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland and to characterise MRSA isolated from cases. Design Prospective surveillance study. Setting Children aged Methods Cases were ascertained by active surveillance involving paediatricians reporting to the British Paediatric Surveillance Unit and by routine laboratory surveillance. Patient characteristics were obtained using questionnaires sent to reporting paediatricians. MRSA isolates were characterised using molecular and phenotypic techniques including antimicrobial susceptibility testing. Results 265 episodes of MRSA bacteraemia were ascertained, involving 252 children. The overall incidence rate was 1.1 per 100 000 child population per year (95% CI 0.9 to 1.2): 61% of the children were aged Conclusions MRSA bacteraemia in children was relatively uncommon and was predominantly seen in very young children, often those receiving neonatal or paediatric intensive care. Bacteraemia predominantly involved well-documented epidemic strains of MRSA associated with nosocomial infection.
- 1 June 2010
- Published by BMJ in Archives of Disease in Childhood
- Vol. 95 (10) , 781-785
Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland
Objective To determine the incidence and demographic features of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland and to characterise MRSA isolated from cases. Design Prospective surveillance study. Setting Children aged Methods Cases were ascertained by active surveillance involving paediatricians reporting to the British Paediatric Surveillance Unit and by routine laboratory surveillance. Patient characteristics were obtained using questionnaires sent to reporting paediatricians. MRSA isolates were characterised using molecular and phenotypic techniques including antimicrobial susceptibility testing. Results 265 episodes of MRSA bacteraemia were ascertained, involving 252 children. The overall incidence rate was 1.1 per 100 000 child population per year (95% CI 0.9 to 1.2): 61% of the children were aged Conclusions MRSA bacteraemia in children was relatively uncommon and was predominantly seen in very young children, often those receiving neonatal or paediatric intensive care. Bacteraemia predominantly involved well-documented epidemic strains of MRSA associated with nosocomial infection.
- Open Access
- 18 July 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (5) , 853-854
The European Antibiotic Awareness Day
The European Antibiotic Awareness Day, which will have as its theme the need to stop unnecessary use of antibiotics, will take place on 18 November 2008. It is hoped that healthcare workers and other professionals, particularly those involved with child care, as well the general public and members of the media, will participate in the various activities and discussions that will take place across Europe as part of this initiative. The European Antibiotic Awareness Day will be an annually recurring event that will raise awareness about the risks associated with inappropriate use of antibiotics and how to use antibiotics responsibly.
- 18 July 2008
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (5) , 853-854
Open AccessThe European Antibiotic Awareness Day
The European Antibiotic Awareness Day, which will have as its theme the need to stop unnecessary use of antibiotics, will take place on 18 November 2008. It is hoped that healthcare workers and other professionals, particularly those involved with child care, as well the general public and members of the media, will participate in the various activities and discussions that will take place across Europe as part of this initiative. The European Antibiotic Awareness Day will be an annually recurring event that will raise awareness about the risks associated with inappropriate use of antibiotics and how to use antibiotics responsibly.
- 1 November 2007
- Published by Elsevier in Journal of Infection
- Vol. 55 (5) , 394-399
Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
- 1 November 2007
- Published by Elsevier in Journal of Infection
- Vol. 55 (5) , 394-399
Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
- Open Access
- 26 March 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (5) , 823-824
Interventions in healthcare-associated infection: researchers urged to CONSORT with ORION
The ORION (Outbreak Reports and Intervention studies Of Nosocomial infection) statement has been prepared by a group of investigators with the expressed purpose of increasing the quality of research and reporting in the area of nosocomial infection. It is hoped that publication of the ORION statement will aid investigators in the design, performance and reporting of studies in this area, and will encourage journals and research councils to incorporate it into their submission and reviewing processes.
- 26 March 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (5) , 823-824
Open AccessInterventions in healthcare-associated infection: researchers urged to CONSORT with ORION
The ORION (Outbreak Reports and Intervention studies Of Nosocomial infection) statement has been prepared by a group of investigators with the expressed purpose of increasing the quality of research and reporting in the area of nosocomial infection. It is hoped that publication of the ORION statement will aid investigators in the design, performance and reporting of studies in this area, and will encourage journals and research councils to incorporate it into their submission and reviewing processes.